Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov sold 10,000 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $6.08, for a total value of $60,800.00. Following the completion of the transaction, the director now directly owns 83,863 shares of the company’s stock, valued at $509,887.04. The trade was a 10.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Rosty Raykov also recently made the following trade(s):

• On Thursday, December 5th, Rosty Raykov sold 796 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.04, for a total value of $4,807.84.
• On Monday, November 4th, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $4.31, for a total value of $10,477.61.

Fennec Pharmaceuticals Price Performance

Fennec Pharmaceuticals stock opened at $6.08 on Thursday. The company has a fifty day simple moving average of $5.51 and a 200-day simple moving average of $5.52. The firm has a market capitalization of $167.02 million, a price-to-earnings ratio of -60.79 and a beta of 0.34. The company has a quick ratio of 7.64, a current ratio of 7.80 and a debt-to-equity ratio of 9.86. Fennec Pharmaceuticals Inc has a 52-week low of $3.96 and a 52-week high of $11.49.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on FENC. Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Tuesday, December 17th. Finally, Wedbush reiterated an “outperform” rating and set a $13.00 price objective on shares of Fennec Pharmaceuticals in a research note on Friday, December 20th.

Institutional Trading of Fennec Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its position in shares of Fennec Pharmaceuticals by 42.8% in the second quarter. Bank of New York Mellon Corp now owns 68,724 shares of the company’s stock valued at $420,000 after purchasing an additional 20,602 shares in the last quarter. Rhumbline Advisers boosted its stake in Fennec Pharmaceuticals by 44.7% during the second quarter. Rhumbline Advisers now owns 29,110 shares of the company’s stock worth $178,000 after buying an additional 8,987 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Fennec Pharmaceuticals in the 2nd quarter valued at $49,000. WINTON GROUP Ltd acquired a new stake in shares of Fennec Pharmaceuticals in the 2nd quarter worth $409,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Fennec Pharmaceuticals during the 2nd quarter worth $69,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.